04.01.2019

Notice Sub: Submission of pending UC, SOE and Claim form

Erythropoietin (EPO) is used in many clinical settings for anaemic patients. Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO as these diseases may cause anemia. A second-generation erythropoietin analogue, Darbepoetin alpha, was created aiming longer elimination half-life in vivo that translated into less frequent dosing, usually once weekly or once every 2 week.

Milk derived primary Mammary Epithelial Cells (pMECs) are potential tools in pursuit of future scientific breakthrough as they represent 90% of in-vivo environment as compared to transformed cells. Lack of commercial availability of pMECs is a problem faced by scientific community.

BCIL Licensed Cardiopulmonary Resuscitation Device technology to M/s Rcupe Lifesciences Pvt Ltd., Bangalore, a start-up company from SIB in the presence of Prof. V. K. Paul, member NITI Aayog, Dr. Renu Swarup, Secretary, DBT and Dr. Balram Bhargava, DG, ICMR & Secretary DHR and other dignitaries. It is a Novel CPR Device developed under the School of International Biodesign (SIB).